MSL (300,000 to 450,000)

Job summary

Industry type

Biopharmaceutical

Recruitment

1

Position Nature

Full time

Work place

Beijing

Salary range

300-450 thousand

shadow

Medicine (300-45 million)

Medicine (300-45 million)

Job Highlights:

The company's 3 core business lines: oncology, respiratory, and immunity are the only approved monoclonal antibody products, and the market and clinical feedback are very good.
The boss is in Beijing, with rich management experience and nice people

Key Accountabilities:

Responsible for belimumab: Benlysta is the only biologic approved for lupus
Indications: SLE: Systemic lupus erythematosus treatment.
New indication: GlaxoSmithKline's belimumab Benlysta for treatment of lupus has increased sales, and will apply to the FDA for the treatment of lupus nephritis in 2020

Responsible for belimumab: Benlysta is the only biologic approved for lupus
Indications: SLE: Systemic lupus erythematosus treatment.
New indication: GlaxoSmithKline's belimumab Benlysta for treatment of lupus has increased sales, and will apply to the FDA for the treatment of lupus nephritis in 2020

In a Phase 3 study called Bliss-LN, 43% of patients with lupus nephritis in the Benlysta group reached the primary endpoint, renal response (a measure of renal function), compared to the control group. Is 32%. Patients in the Benlysta group also showed significantly higher responses at secondary endpoints, including time to death or kidney-related complications.

Sheri Mullen, GSK's senior vice president of specialty pharmaceuticals in the United States, said the data could make Benlysta the first drug approved for the treatment of lupus nephritis, thereby expanding the patient population of the product and will submit applications in the first half of 2020 To the FDA.

Sheri Mullen, GSK's senior vice president of specialty pharmaceuticals in the United States, said the data could make Benlysta the first drug approved for the treatment of lupus nephritis, thereby expanding the patient population of the product and will submit applications in the first half of 2020 To the FDA.

Benlysta is the only biologic approved for lupus. In the first nine months of 2019, Benlysta's global sales were $ 581 million, a 32% increase over the same period last year.

GSK said that increasing the indications could further increase sales of the drug, with about 60% of 328,000 patients with severe lupus in the United States suffering from lupus nephritis each year.

Competence Profile:

Medical / Immune Background, prefer MSL, Clinical Specialty

Please log in before applying for a job

shadow